share_log

和黃醫藥：授出認股權計劃項下的認股權及長期獎勵計劃項下的獎勵

HUTCHMED: Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

香港交易所 ·  Mar 14 05:04
Summary by Moomoo AI
和黃醫藥（中國）有限公司於2024年3月13日宣布，根據2015年採納的認股權計劃及長期獎勵計劃，向執行董事蘇慰國博士授出績效相關認股權及非績效相關的長期獎勵計劃獎勵。該認股權計劃授出的認股權數目為1,359,561股普通股，行使價為每股28.35港元，並設有表現目標。非績效相關的長期獎勵計劃獎勵則為一筆500,000美元的現金款項，用於購買公司股份。此舉旨在吸引及挽留頂尖人才，並已獲獨立非執行董事批准。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三個藥物在中國獲批上市，其中一個亦在美國上市。
和黃醫藥（中國）有限公司於2024年3月13日宣布，根據2015年採納的認股權計劃及長期獎勵計劃，向執行董事蘇慰國博士授出績效相關認股權及非績效相關的長期獎勵計劃獎勵。該認股權計劃授出的認股權數目為1,359,561股普通股，行使價為每股28.35港元，並設有表現目標。非績效相關的長期獎勵計劃獎勵則為一筆500,000美元的現金款項，用於購買公司股份。此舉旨在吸引及挽留頂尖人才，並已獲獨立非執行董事批准。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三個藥物在中國獲批上市，其中一個亦在美國上市。
HE HUANG PHARMACEUTICALS (CHINA) CO., LTD. ANNOUNCED ON 13 MARCH 2024 THAT IT HAS AWARDED PERFORMANCE RELATED AUTHORIZATION AND NON-PERFORMANCE RELATED LONG-TERM BONUS SCHEME AWARDS TO EXECUTIVE DIRECTOR DR. SU JIU-KUO UNDER THE 2015 WARRANT AND LONG-TERM INCENTIVE PLAN. The number of warrants granted under the Share Option Scheme is 1,359,561 shares of ordinary shares at an exercise price of HK$28.35 per share and has performance targets. Non-performance-related long-term incentive plan rewards are a $500,000 cash payment used to purchase company shares. The move is aimed at attracting and retaining top talent and has been approved by an independent non-executive director. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases. Three drugs have been approved in China, including one in the United States.
HE HUANG PHARMACEUTICALS (CHINA) CO., LTD. ANNOUNCED ON 13 MARCH 2024 THAT IT HAS AWARDED PERFORMANCE RELATED AUTHORIZATION AND NON-PERFORMANCE RELATED LONG-TERM BONUS SCHEME AWARDS TO EXECUTIVE DIRECTOR DR. SU JIU-KUO UNDER THE 2015 WARRANT AND LONG-TERM INCENTIVE PLAN. The number of warrants granted under the Share Option Scheme is 1,359,561 shares of ordinary shares at an exercise price of HK$28.35 per share and has performance targets. Non-performance-related long-term incentive plan rewards are a $500,000 cash payment used to purchase company shares. The move is aimed at attracting and retaining top talent and has been approved by an independent non-executive director. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases. Three drugs have been approved in China, including one in the United States.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more